iFCG yields unprecedented MRD negativity in CLL

iFCG yields unprecedented MRD negativity in CLL

VJHemOnc

1 year
64 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
FCR chemoimmunotherapy is most effective in the IGVH mutated, non-17p deletion chronic lymphocytic leukemia (CLL) patient subgroup. With the advent of novel drugs in the field however, Nitin Jain, MD, from the MD Anderson Cancer Center, Houston, TX, believes that this therapy could be improved upon. In this interview, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, he discusses the rationale behind, and results from, his trial (NCT02629809) investigating the effect of iFCG, a combination therapy including ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab. Boasting minimal residual disease negativity rates of over 90%, this treatment option has huge potential.
Up Next Autoplay
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
11 Views
ash 1 day
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 2 days
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 2 days
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Category: Chronic Lymphocytic Leukemia
6 Views
ash 3 days
SWAY Study @LevineCancer #ASH19
SWAY Study @LevineCancer #ASH19
Category: Chronic Lymphocytic Leukemia
0 Views
ash 3 days
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 3 days
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
2 Views
ash 3 days
Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC
Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC
Category: Chronic Lymphocytic Leukemia
0 Views
ash 3 days
Phase 2 CAPTIVATE clinical trial in CLL #ASH19 #ASH @PeterMacCC
Phase 2 CAPTIVATE clinical trial in CLL #ASH19 #ASH @PeterMacCC
Category: Chronic Lymphocytic Leukemia
1 Views
ash 3 days
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
Category: Chronic Lymphocytic Leukemia
2 Views
Cancer-News 5 days